Abstract: 〔Abstract〕Objective：To evaluate the safety and efficacy of such second-line drugs as danazol, rituximab and recombinant human
thrombopoietin（rhTPO）in treating adult primary immune thrombocytopenia（ITP）. Methods：The clinical data of 74 patients with
immunological thrombocytopenia were collected. The patients were divided into three groups treated with the three drugs respectively,
and then a retrospective analysis was made. Results: There were no differences between the rhTPO group and the rituximab group（P＞
0.05）, and there were differences between the above-mentioned two groups and the danazol group（P＜0.05）. Conclusion: All the
three drugs are effective. Rituximab group and rhTPO group have the same efficacy and are significantly better than danazol group.

Key words: 〔Key words〕adult primary immune thrombocytopenia, danazol, rituximab, recombinant human thrombopoietin（rhTPO）